DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced the settlement of the remaining $84.8 million aggregate principal amount of 2.5% unsecured convertible senior notes due May …
Category: Business
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
GENEVA–(BUSINESS WIRE)–Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
GENEVA–(BUSINESS WIRE)–Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neu…
GenSight Biologics annonce l’approbation de l’ensemble des résolutions soutenues par le Conseil d’Administration lors de son assemblée générale mixte du 13 mai 2025
PARIS–(BUSINESS WIRE)–Regulatory News: L’Assemblée Générale Mixte des actionnaires de la société GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation…
GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025
PARIS–(BUSINESS WIRE)–Regulatory News: The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies…
Glaukos Announces Participation in Upcoming Investor Conferences
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today…
$7.22 Bn OTC Artificial Tears Market Size, Share Analysis, Growth Trends and Forecasts 2024-2025 & 2033 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “OTC Artificial Tears Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033” report has been added to ResearchAndMarkets.com’s offering. The OTC Artificial Tears market is expected to grow from US$ 4….
Vision Care Market Forecast Report and Company Analysis 2025-2033 Featuring Essilor, J&J, Bausch Health, Novartis, Grand Vision, Carl Zeiss, Valeant Pharma, Paragon Vision Science, and Menicon – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Vision Care Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033” report has been added to ResearchAndMarkets.com’s offering. The Vision Care Market is anticipated to rise at a compound annual growt…
Warby Parker Announces First Quarter 2025 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2025. “Our team deliver…
LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects
SEATTLE–(BUSINESS WIRE)– #DryAMD–LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects Treated with Valeda
Amgen’s TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom
CAMBRIDGE, England–(BUSINESS WIRE)–Today, Amgen announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as the first therapy specifically licensed for the trea…
Alcon Announces Results of 2025 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Announces Results of 2025 Annual General Meeting
Alcon Announces Results of 2025 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Announces Results of 2025 Annual General Meeting
Breakthrough Gene Therapies Poised to Transform Cone Rod Dystrophy Treatment Landscape – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Cone Rod Dystrophy Market: Analysis By Type, By Treatment Type, By End User, By Region Size and Trends – Forecast up to 2030” has been added to ResearchAndMarkets.com’s offering. As of 2024, the global cone rod dystrophy m…
OcuSciences Announces FDA Marketing Clearance of OcuMet Beacon in Retinal Health Assessment at ARVO
ANN ARBOR, Mich.–(BUSINESS WIRE)–OcuSciences, Inc., a leader in advanced ocular diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its flagship device, the OcuMet Beacon, proprietary, non-invasive …
Glaukos Announces First Quarter 2025 Financial Results
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financ…
Bausch + Lomb Announces First-Quarter 2025 Results
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results. “Our core business is pe…
Bausch + Lomb Announces First-Quarter 2025 Results
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results. “Our core business is pe…